Glucosamine powder for solution for oral administration 1.5 g in bags No. 20

Name:
Glucosamine por.d/prig.r-ra for pr.vn.1.5 g in a package in pack No. 20
Description:
Powder consisting of particles of varying degrees of grinding, from white to white with a yellowish or white with a grayish tint. The main active substance Glucosamine Product form Powder for solution Pharmacological action Glucosamine hydrochloride is a salt of glucosamine aminomonosaccharide, which is an endogenous component and a preferred substrate for the synthesis of glycosaminoglycans and proteoglycans of articular cartilage and synovial fluid. Glucosamine inhibits the activity of interleukin-1-? and other inflammatory mediators. Clinical Efficacy and Tolerability: The safety and efficacy of glucosamine has been confirmed in clinical trials with treatment durations up to three years. Short- and medium-term clinical studies have shown that the effectiveness of glucosamine in relation to the symptoms of osteoarthritis is observed after 2-3 weeks of its use. However, unlike NSAIDs, glucosamine has a long-lasting effect that lasts from 6 months to 3 years. Clinical studies with daily glucosamine for up to 3 years have shown a gradual improvement in disease symptoms and a slowdown in structural changes in the joint, as demonstrated by plain radiography. Glucosamine has been shown to be well tolerated over short and long-term courses of treatment. Evidence of the effectiveness of the drug was demonstrated when it was taken for three months, with a residual effect for two months after its withdrawal. The safety and efficacy of the drug have also been confirmed in clinical trials for up to three years of use. Continuous treatment for more than 3 years cannot be recommended, as there are no safety data when taking glucosamine for more than 3 years. Indications for use Relief of symptoms (mild to moderate pain) in adequately diagnosed osteoarthritis of the knee. Dosing and Administration Inside, one packet (1500 mg) 1 time per day, preferably with meals. The contents of one packet should be dissolved in a glass of water. The duration of treatment is usually 4-6 weeks. Treatment courses, if necessary, are repeated at intervals of 2 months. Glucosamine is not intended for the treatment of acute pain symptoms. Relief of symptoms (especially pain relief) may occur only after several weeks of use, and sometimes longer. If symptoms are not relieved after 2-3 months, continued glucosamine treatment should be reconsidered. Patients should seek medical advice if pain worsens after starting glucosamine. Elderly patients: Dosage adjustment in elderly patients is not required. Patients with impaired renal and/or hepatic function: Studies of the use of glucosamine in patients with impaired renal and/or hepatic function have not been conducted, therefore, there are no dosage recommendations for such patients. Children and adolescents: Glucosamine should not be used in children and adolescents under the age of 18 years, as there are no data on the safety and efficacy of glucosamine in this category of patients. Use during pregnancy and lactation Studies on the efficacy and safety of the use of glucosamine in pregnant and lactating women have not been conducted, so the drug is not recommended for women during pregnancy and lactation. Influence on the ability to drive vehicles and other potentially dangerous mechanisms No studies have been conducted on the effect of glucosamine on the ability to drive vehicles and other potentially dangerous mechanisms. You should refrain from driving vehicles and other mechanisms in case of drowsiness, dizziness, fatigue, headache or visual impairment. Precautions Before using glucosamine, you should consult your doctor to exclude the presence of joint diseases for which other methods of treatment are provided. Cases of exacerbation of symptoms of bronchial asthma after the start of taking glucosamine are described. In patients with bronchial asthma, the symptoms of the disease may worsen. Glucosamine should be used with caution in patients with diabetes mellitus. Patients who have been diagnosed with impaired glucose tolerance should have their blood glucose measured before starting treatment, as well as regularly during treatment and, if necessary, change the dose of insulin. The sorbitol contained in the medicinal product can cause osmotic diarrhea. Special studies in patients suffering from impaired renal and / or liver function have not been conducted. According to the toxicological and pharmacokinetic studies of glucosamine in such patients, the dose should not be limited. However, the use of glucosamine in patients with severe renal or hepatic insufficiency should be carried out under the supervision of a physician. Interactions with other drugs Special studies of the interaction of glucosamine with other drugs have not been conducted, therefore, glucosamine should be used in combination with other drugs with caution. There are reports of an increased effect of coumarin anticoagulants, so in patients who are simultaneously taking coumarin anticoagulants (for example, warfarin or acenocoumarol), more careful monitoring of coagulation parameters is necessary. Oral administration of glucosamine may increase the absorption of tetracyclines from the gastrointestinal tract, but the clinical significance of this interaction is low. The drug is compatible with non-steroidal anti-inflammatory drugs and glucocorticosteroids. Contraindications Hypersensitivity to glucosamine or any of the excipients. The powder contains aspartame, so the drug is contraindicated in patients with phenylketonuria. Powder for oral solution contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine. The drug should not be prescribed to patients suffering from shellfish allergy, because. the active substance (glucosamine) is obtained from mollusks and crustaceans. Pregnancy and the period of breastfeeding. Composition Each package contains: active substance: glucosamine hydrochloride – 1.5 g; excipients: macrogol 4000, flavor “Lemon PX1548”, citric acid monohydrate, aspartame, sorbitol. Overdose No cases of accidental or intentional overdose are known. In case of an overdose, glucosamine should be discontinued, treatment is symptomatic, aimed at restoring the water and electrolyte balance. Side effects The frequency of side effects is given in the following gradation: very often (? 1/10); often (? 1/100, < 1/10); infrequently (? 1/1000, < 1/100); rarely (? 1/10000, < 1/1000); very rarely (< 1/10000); unknown (according to the available data, it is not possible to determine the frequency of occurrence). The most common adverse reactions associated with oral glucosamine are nausea, abdominal pain, dyspepsia, flatulence, constipation, and diarrhea. These adverse reactions, as a rule, were moderately severe and transient. From the immune system: unknown: allergic reactions *. From the side of metabolism and nutrition: unknown: inadequate glycemic control in diabetes. From the nervous system: often: headache, drowsiness; unknown: dizziness, insomnia. On the part of the organ of vision: unknown: visual impairment. From the side of the cardiovascular system: infrequently: hot flashes; unknown: arrhythmias, including tachycardia. On the part of the respiratory system, chest and mediastinum: unknown: asthma / worsening of asthma. From the gastrointestinal tract: often: diarrhea, constipation, nausea, flatulence, abdominal pain, dyspepsia; unknown: vomiting. On the part of the skin and subcutaneous tissue: infrequently: erythema, itching, rash; unknown: angioedema, urticaria. From the hepatobiliary system: unknown: jaundice, increased liver enzymes**. General disorders: often: fatigue; unknown: edema/peripheral edema. From the side of laboratory and physiological parameters, it is unknown: an increase in "liver" enzymes, blood glucose levels, an increase in blood pressure, fluctuations in the INR index. *Severe allergic reactions to glucosamine may occur in susceptible patients. ** Cases of jaundice and elevated liver enzymes have been reported, but a causal relationship has not been established. Cases of hypercholesterolemia have been reported, but a causal relationship with glucosamine use has not been demonstrated. In the event of the listed adverse reactions, as well as reactions not listed in the instructions, you should consult a doctor. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Glucosamine powder for oral solution 1.5g in bags #20 Price for Glucosamine powder for oral solution 1.5g in bags #20 Instructions for use for Glucosamine powder for oral solution inside 1.5 g in bags No. 20